Quantcast

Latest Clostridium difficile Stories

2014-07-29 12:36:03

ROCKVILLE, Md., July 29, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that in view of the unusual market activity in the Company's stock, the NYSE MKT (the "Exchange") has contacted the Company in accordance with its usual practice. The Company stated that its policy is not to comment on unusual market activity....

2014-07-23 12:31:01

Researchers found that a considerable proportion of infections were discovered outside the hospital setting PASADENA, Calif., July 23, 2014 /PRNewswire/ -- More than 80 percent of hospitalized patients who tested positive for Clostridium difficile were tested outside the hospital or within the first 72 hours of hospitalization, suggesting that settings outside of the hospital may play key roles in the identification, onset and possible transmission of the disease, according to a new...

2014-07-16 08:29:22

SER-109 demonstrated remarkably high clinical cure rate and excellent safety profile CAMBRIDGE, Mass., July 16, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that it has completed enrollment for its single-arm, open-label clinical trial of SER-109, its first-in-field, oral microbiome therapeutic designed for the treatment of recurrent Clostridium difficile Infection...

2014-07-07 16:23:01

LONDON, July 7, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:MarketVIEW: Clostridium difficile vaccines http://www.reportbuyer.com/pharma_healthcare/therapeutic/marketview_clostridium_difficile_vaccines.htmlClostridium difficile (C.diff) is a Gram-positive bacterium, which in vulnerable hospitalized patients can cause gastrointestinal infections (CDI). Outcomes range from mild uncomplicated diarrhea to severe-complicated disease where patients...

2014-07-07 12:28:38

Company's Breakthrough Innovation to Enable First Therapeutics for Microbiome-based Diseases CAMBRIDGE, Mass., July 7, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pharmaceutical composition patent application that covers its lead product candidate, SER-109, which is currently...

2014-06-30 08:29:30

-- Company Expects to Initiate C. difficile Clinical Trials in 2014 -- ROCKVILLE, Md., June 30, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating...

2014-06-19 04:21:30

LAUSANNE, Switzerland, June 19, 2014 /PRNewswire/ -- Debiopharm Group(TM)(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known...

2014-06-18 16:26:41

GERMANTOWN, Maryland, and HILDEN, Germany, June 18, 2014 /PRNewswire/ -- - Assay offers faster quantification of CMV DNA levels in patient samples - Up to 60% of all transplant patients are repeatedly tested for CMV viral load to help avoid potentially life-threatening conditions caused by this virus - PMA approval of artus(R) CMV RGQ MDx Kit adds further value to the QIAsymphony modular family of automated instruments as the...

2014-06-17 12:37:42

American Society for Microbiology Fecal microbiota transplantation --- the process of delivering stool bacteria from a healthy donor to a patient suffering from intestinal infection with the bacterium Clostridium difficile --- works by restoring healthy bacteria and functioning to the recipient's gut, according to a study published this week in mBio®, the online open-access journal of the American Society for Microbiology. The study provides insight into the structural and potential...

2014-06-10 04:22:10

-- Study to Define Impact of Beta-Lactam Antibiotics on Intestinal Bacteria -- ROCKVILLE, Md. and PARIS, June 10, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, today announced...


Latest Clostridium difficile Reference Libraries

0_9f897835bb09adc2a84fda23893d87f8
2011-04-15 13:50:01

Clostridium difficile, also known as "CDF/cdf", or "C. diff", is a Gram-positive bacteria of the genus Clostridium that causes severe diarrhea and other intestinal disease when competing bacteria in the gut flora are wiped out by antibiotics. They are anaerobic, spore-forming rods and is the most serious cause of antibiotic-associated diarrhea and potentially to pseudomembranous colitis. C. difficile bacteria naturally resides in the gut of a small percentage of the adult population. Others...

More Articles (1 articles) »
Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related